Vivos Therapeutics (VVOS) Operating Leases (2021 - 2026)

Vivos Therapeutics (VVOS) has 6 years of Operating Leases data on file, last reported at $3.7 million in Q1 2026.

• Quarterly Operating Leases rose 291.95% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (up 291.95% YoY) and the FY2025 annual result came in at $3.8 million, up 271.01% from the prior year.
• Operating Leases fell to $3.7 million in Q1 2026 per VVOS's latest filing, from $3.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $3.8 million in Q4 2025 and bottomed at $932000.0 in Q1 2025.
• The 5-year median for Operating Leases is $2.0 million (2022), against an average of $2.1 million.
• The widest annual swing landed in 2024, when Operating Leases slumped 44.96%; it then surged 291.95% in 2026.
• Tracing VVOS's Operating Leases over 5 years: stood at $2.0 million in 2022, then retreated by 23.72% to $1.5 million in 2023, then sank by 31.95% to $1.0 million in 2024, then jumped by 271.01% to $3.8 million in 2025, then dropped by 4.87% to $3.7 million in 2026.
• Per Business Quant, the three latest VVOS Operating Leases figures stand at $3.7 million (Q1 2026), $3.8 million (Q4 2025), and $2.9 million (Q3 2025).

Peer Comparison